The review objective is to determine the current evidence related to the effectiveness of BLT on depressive symptoms in older adults with non-seasonal depression.
Depressive symptoms are common psychiatric comorbidities among individuals receiving long-term hemodialysis. The aim of this two-arm parallel design study is to assess the effects of bright light therapy (BLT) on depressive symptoms among middle-aged and older adults receiving long-term hemodialysis. Study participants are recruited using convenient sampling from four dialysis clinics in eastern Taiwan. The eligible participants are block-randomized to either the BLT group (n = 30), with 30 min sessions of BLT five times a week for six weeks at their own home, or to the routine care control group (n = 30). The Beck Depression Inventory-II (BDI-II) scores and the salivary cortisol levels are obtained from the participants at three time points: baseline (T0), week 3 (T1), and week 6 (T2). The results, from the generalized estimating equations, indicate that the decline in the BDI-II scores over time is significant in the BLT group at T1 (β = −7.57, p < 0.001) and at T2 (β = −6.20, p = 0.002) compared to the control group. The decrease in salivary cortisol levels at each visit is also significant in the BLT group at T1 (β = −7.37, p = 0.017) and at T2 (β = −12.22, p = 0.005) compared to the control group. Our findings support the hypothesis that a six-week program of BLT is able to alleviate depressive symptoms in middle-aged and older patients who receive long-term hemodialysis.
Objectives: Opioid Use Disorder (OUD) is a chronic brain disease that can be successfully managed with buprenorphine (BPN). Like other chronic diseases, OUD involves cycles of relapse and remission, with relapse often associated with medication treatment discontinuation. This study seeks to characterize the relationship between healthcare expenditures and OUD patient relapse and to evaluate real-world BPN treatment persistence. Methods: This retrospective observational study of patients with OUD enrolled in commercial, Medicare and Medicaid plans included claims data incurred between 01/01/2011 and 03/31/2018. Patients were required to have a minimum of two years of follow up and were split into three cohorts: OUD with relapse, OUD without relapse, and control (treated with acute opioids). A 1:1:1 propensity score match was performed. Results: 3,630 propensity matched patients from each of the cohorts qualified for the analysis with 71% enrolled in a Medicaid plan. Highest rates of anxiety, bipolar disorder, depression, and hepatitis C were found for OUD patients with relapse. OUD patients with relapse also incurred greater per member medical costs ($28,944) as compared to OUD patients without relapse ($18,252), and control ($11,880) (p=0.0203). Among patients with OUD, costs related to opioid dependence were higher for the relapsing cohort ($10,383) as compared to the non-relapsing cohort ($3,550) (p=0.0203). OUD patients demonstrated low persistence in buprenorphine treatment for both the relapsing (125 mean days in treatment episode) and non-relapsing (173 days) cohorts. Conclusions: In patients with OUD, relapse (as compared to no relapse) was associated with an increase in medical utilization that resulted in greater annual medical spend. Improved methods to identify patients with OUD in need of additional interventions and methods to prolong medication treatment duration are needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.